Ethris is a privately-held German biotechnology company developing messenger RNA therapeutics for pulmonary disorders. Our pipeline is based on Ethris' proprietary SNIM(R)RNA platform, which incorporates multiple mRNA design elements to produce highly active and non-immunogenic mRNA payloads into nanoparticles, for delivery by nebulization to address disorders of the respiratory tract. Ethris' pipeline is focused on orphan genetic pulmonary diseases, and we collaborate with AstraZeneca in the areas of asthma, COPD, and idiopathic pulmonary fibrosis. Ethris' lead program, ETH42, is in preclinical development for primary ciliary dyskinesia, with a first in man study planned for initiation in 2020.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):